Insights

Acquisition Fit ViaCyte is now part of Vertex, indicating potential cross-sell opportunities for Vertex’s broader portfolio and integration of stem cell and regenerative medicine capabilities into existing Vertex programs.

Strategic Growth Vertex’s ongoing late-stage programs (e.g., inaxaplin for APOL1-related kidney disease) suggest opportunities to expand collaborations or leverage Vertex’s platform to accelerate related renal disease or genetic condition initiatives.

Financial Leverage Vertex reports modest revenue with substantial funding and cost-deferral dynamics; sales conversations could target co-development or financing partnerships to de-risk early-stage programs and scale manufacturing.

Clinical Momentum Active partnerships and significant patient initiations in Vertex’s pipeline imply readiness to engage with CROs, contract manufacturers, or data/analytic services to support accelerating trials and regulatory submissions.

Tech & Data Enablement Vertex’s diverse tech stack and reliance on advanced data operations present an opportunity to offer specialized software, data integration, and collaboration tools to streamline research, trials, and operations across merged teams.

Similar companies to ViaCyte

ViaCyte Tech Stack

ViaCyte uses 8 technology products and services including Apache Spark, AutoCAD, PostgreSQL, and more. Explore ViaCyte's tech stack below.

Media & News

ViaCyte's Email Address Formats

ViaCyte uses at least 7 email formats:
ViaCyte Email FormatsExamplePercentage
FLast@viacyte.comJDoe@viacyte.com
94%
First.Last@viacyte.comJohn.Doe@viacyte.com
4%
Last@viacyte.comDoe@viacyte.com
2%
First_Last@vrtx.comJohn_Doe@vrtx.com
62%
First.Last@vrtx.comJohn.Doe@vrtx.com
34%
LastF@vrtx.comDoeJ@vrtx.com
2%
Last@vrtx.comDoe@vrtx.com
2%

Frequently Asked Questions

What is ViaCyte's phone number?

Minus sign iconPlus sign icon
You can contact ViaCyte's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is ViaCyte's official website and social media links?

Minus sign iconPlus sign icon
ViaCyte's official website is vrtx.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does ViaCyte generate?

Minus sign iconPlus sign icon
As of October 2026, ViaCyte's annual revenue is estimated to be $10M - $25M.

What is ViaCyte's SIC code and NAICS code?

Minus sign iconPlus sign icon
ViaCyte's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does ViaCyte have currently?

Minus sign iconPlus sign icon
As of October 2026, ViaCyte has approximately 14 employees across 2 continents, including North America and South America. Key team members include Chief Financial Officer: L. M., Owner: A. B. and Vice-President: M. S. Explore ViaCyte's employee directory with LeadIQ.

What industry does ViaCyte belong to?

Minus sign iconPlus sign icon
ViaCyte operates in the Biotechnology Research industry.

What technology does ViaCyte use?

Minus sign iconPlus sign icon
ViaCyte's tech stack includes Apache Spark, AutoCAD, PostgreSQL, Sketch, Agentforce, Smartsheet, Microsoft Teams and Zoom.

What is ViaCyte's email format?

Minus sign iconPlus sign icon
ViaCyte's email format typically follows the pattern of FLast@viacyte.com. Find more ViaCyte email formats with LeadIQ.

How much funding has ViaCyte raised to date?

Minus sign iconPlus sign icon
As of October 2026, ViaCyte has raised $236M in funding. The last funding round occurred on Apr 22, 2021.
ViaCyte logo

ViaCyte

Biotechnology ResearchCalifornia, United States11-50 Employees

ViaCyte operates in biotechnology research and is now part of Vertex Pharmaceuticals. The company is based in San Diego, California, and maintains a small-to-mid-sized workforce. As part of Vertex, ViaCyte sits within a global organization focused on delivering innovative therapies for people with serious diseases.

Vertex has publicly signaled expansion of its gene editing and gene therapy capabilities, reflecting a strategic emphasis on genetic therapeutics. Within this environment, ViaCyte is positioned as part of a broader effort to advance therapies for serious diseases.

Section iconCompany Overview

Phone number
Website
vrtx.com
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconFunding & Financials

  • $236M

    ViaCyte has raised a total of $236M of funding over 15 rounds. Their latest funding round was raised on Apr 22, 2021 as a Series D.

  • $10M - $25M

    ViaCyte's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.